TP53 and Myelodysplasia: Additionally, outcomes of patients with NPM1-mutated AML and co-occurring mutations of TP53 (Table S4, Fig. S2) as well as NPM1-mutated AML with co-occurring myelodysplasia-related cytogenetic changes (Table S5, Fig. S3) were evaluated.